News Search Results
Apr 01, 2025, 05:00 ET Plant Biotechnology Market worth $76.79 billion by 2030- Exclusive Report by MarketsandMarkets™
biopesticides sub-segment hold the significant market share in the crop protection & nutrition solutions segment for plant biotechnology. Advances in plant biotechnology have contributed significantly towards the development of biopesticides. Such developments as RNA interference (RNAi) technology
More news about: MarketsandMarkets
Mar 31, 2025, 16:30 ET Carisma Therapeutics Provides Corporate Updates
and prepare for a potential wind-down of operations, if necessary.About Carisma Therapeutics Carisma Therapeutics is a biotechnology Company pioneering macrophage engineering to develop groundbreaking therapies for fibrosis and cancer. With a strong commitment to patient-centric
More news about: Carisma Therapeutics Inc.
Mar 31, 2025, 16:15 ET Thunder Power Holdings, Inc. Announces Financial Results and Strategic Developments
Nasdaq Capital Market benefits smaller companies focused on raising capital and lists a wide variety of companies, including those from technology, biotechnology, and other sectors. "We believe listing on the Nasdaq Capital Market is more reflective of AIEV at this stage in our development, allowing
More news about: Thunder Power Holdings, Inc.
Mar 31, 2025, 12:43 ET INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
March 31, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and certain officers. The class action, filed in the United States
More news about: Pomerantz LLP
Mar 31, 2025, 10:15 ET Clinical Trial Supplies Market worth $8.18 billion in 2030 with 8.9% CAGR | MarketsandMarkets™
sourcing of comparator drugs. By end users, the market is segmented into pharmaceutical & biotechnology companies, CROs & CDMOs and Other end users. Pharmaceutical & biotechnology companies dominated the segment in 2024 and is anticipated to grow at the highest significant CAGR during
More news about: MarketsandMarkets
Mar 31, 2025, 09:59 ET Crown Laboratories Now Operates Under the Name Revance
change marks a significant milestone in the company's strategic transformation following its recent acquisition of Revance Therapeutics, Inc., a biotechnology company known for its cutting edge innovation in aesthetics and therapeutics, which joins Crown's deep roots in science-driven brands for skin health
More news about: Crown Laboratories, Inc.
Mar 31, 2025, 09:30 ET ICLR Deadline: ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
were insufficient to shield ICON from the adverse effects of a significant market downturn; (3) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: THE ROSEN LAW FIRM, P. A.
Mar 31, 2025, 08:30 ET Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications
commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Mar 31, 2025, 08:00 ET Orna Therapeutics Appoints Joseph Bolen, Ph.D., as Chief Executive Officer
WATERTOWN, Mass., March 31, 2025 /PRNewswire/ -- Orna Therapeutics, a biotechnology company dedicated to engineering immune cells in vivo to treat oncology and autoimmune diseases, today announced the appointment of
More news about: Orna Therapeutics
Mar 31, 2025, 08:00 ET Curis Provides Fourth Quarter 2024 Business Update
Mass., March 31, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update
More news about: Curis, Inc.
Mar 31, 2025, 07:30 ET Transcend Therapeutics Announces Primary Endpoint Met in IMPACT-1 Phase 2 Study of TSND-201 in PTSD
Transcend Therapeutics, a clinical-stage biotechnology company that develops medicines to treat neuropsychiatric diseases, today announced positive results from the IMPACT-1 study (Investigation of Methylone
More news about: Transcend Therapeutics
Mar 31, 2025, 07:30 ET Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange
More news about: Palatin Technologies, Inc.
Mar 31, 2025, 06:13 ET Harbour BioMed Reports Full Year 2024 Financial Results
support collaborators from Idea to IND (I to ITM). Nona Biosciences is a global biotechnology company committed to providing integrated solutions for partners worldwide, across academia, biotechnology startups, and biopharmaceutical giants. Since its launch in late 2022, Nona Biosciences has
More news about: Harbour BioMed
Mar 31, 2025, 06:00 ET Allozymes and Bonumose Collaborate to Accelerate Enzyme Innovations for Beneficial Food & Supplement Ingredients
reduce development timelines and enhance performance, setting a new benchmark in the industry." About Allozymes Allozymes is a biotechnology company that stands out in the bio-engineering sector with its proprietary ultra-high throughput microfluidics platform for the rapid and cost-effective
More news about: Allozymes
Mar 31, 2025, 06:00 ET Allozymes and Bonumose Collaborate to Accelerate Enzyme Innovations for Beneficial Food & Supplement Ingredients
reduce development timelines and enhance performance, setting a new benchmark in the industry." About Allozymes Allozymes is a biotechnology company that stands out in the bio-engineering sector with its proprietary ultra-high throughput microfluidics platform for the rapid and cost-effective
More news about: Allozymes
Mar 31, 2025, 05:45 ET The Gross Law Firm Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SANA
March 31, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
More news about: The Gross Law Firm
Mar 31, 2025, 05:45 ET Investors who lost money on ICON Public Limited Company(ICLR) should contact The Gross Law Firm about pending Class Action - ICLR
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: The Gross Law Firm
Mar 30, 2025, 14:30 ET Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Mar 30, 2025, 07:10 ET Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification
elebsiran for the Greater China territory from Vir Biotechnology, Inc. in 2020. About Brii Bio Brii Biosciences Limited ("Brii Bio", stock code: 2137.HK) is a biotechnology company developing therapies to address major public
More news about: Brii Biosciences Limited
Mar 30, 2025, 07:10 ET 騰盛博藥在2025年亞太肝病學會年會（APASL）上公佈其正在進行的2期ENSURE研究的新數據，表明BRII-179有望通過目標患者識別提高HBsAg清除率
Elebsiran是一種經皮下注射給藥的靶向HBV的siRNA研究性藥物，旨在降解乙型肝炎病毒RNA轉錄本及限制乙型肝炎表面抗原的產生，其具有針對HBV及HDV的直接抗病毒活性。其是首個進入臨床的採用增強穩定化學增強技術的siRNA，以增強穩定性並最大程度地減少脫靶活性，從而有可能提高治療指數。騰盛博藥於2020年從Vir Biotechnology, Inc.獲得了在大中華地區開發和商業化elebsiran的獨家權益。 關於騰盛博藥 騰盛博藥（股票代碼：2137.HK）是一家生物技術公司，致力於針對存在巨大未被滿足的患者需求、治療手段有限，以及給患者帶來嚴重社會歧視的重大公共衛生挑戰開發創
More news about: 騰盛博藥生物科技有限公司
Mar 28, 2025, 16:07 ET Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025
Mass., March 28, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company
More news about: Curis, Inc.
Mar 28, 2025, 16:00 ET Virion Therapeutics Reports Positive Clinical Data with VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure, at APASL 2025 Global Liver Meeting
March 28, 2025 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing novel T cell-based immunotherapies, announced favorable safety and tolerability and immunogenicity data, as well
More news about: Virion Therapeutics, LLC
Mar 28, 2025, 10:30 ET Analytical Standards Market worth US$2.16 billion by 2030 with 5.9% CAGR | MarketsandMarkets™
analytical techniques in proteomics and metabolomics. Additionally, drug development adhering to GMP regulations; the expansion of pharmaceutical & biotechnology industries; and the increasing number of clinical trials are expected to create opportunities for market growth during the forecast period.
More news about: MarketsandMarkets
Mar 28, 2025, 10:12 ET Cytogenetics Market Projected to Reach $5.5 Billion by 2031, Growing at a CAGR of 9.6% from 2024 --Exclusive Report by Meticulous Research®
market segment, driven by the growing adoption of cytogenetic techniques in routine diagnostics and translational research. Pharmaceutical and biotechnology companies are also key contributors, leveraging cytogenetics in drug discovery and clinical trials. Request a customized research analysis
More news about: Meticulous Market Research Pvt. Ltd.
Mar 28, 2025, 10:05 ET INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and reminds investors of the May 20, 2025 deadline to seek the
More news about: Faruqi & Faruqi, LLP